Movantik is a medication used to treat opioid-induced constipation (OIC) in adults with chronic non-cancer pain [1][2]. It is a peripherally acting mu-opioid receptor antagonist (PAMORA) [3].
How does Movantik work?
Movantik works by blocking the effects of opioids on the mu-opioid receptors in the gastrointestinal tract [3]. Opioids can slow down bowel movements, leading to constipation. By blocking these receptors in the gut, Movantik helps to restore normal bowel function without interfering with the pain-relieving effects of opioids in the brain [1][3].
When can I expect Movantik to become available generically?
The first Movantik patent is set to expire in July 2029 [4]. Another patent expires in September 2030 [4].
What are the potential side effects of Movantik?
The most common side effects of Movantik include diarrhea, nausea, abdominal pain, and gas [1]. Serious side effects can include severe abdominal pain and diarrhea, which may lead to dehydration and electrolyte imbalances [1][5]. Patients who experience withdrawal symptoms should contact their doctor [5].
How does Movantik compare to other OIC treatments?
Movantik is one of several PAMORAs available for OIC. Other medications in this class include Relistor (methylnaltrexone bromide) and Entereg (alvimopan) [3]. The choice of treatment often depends on individual patient factors, including the severity of OIC, other medical conditions, and potential drug interactions [3].
Can I use Movantik if I have cancer pain?
Movantik is indicated for adults with chronic non-cancer pain. It is not intended for use in patients with cancer pain [1][2].